Tagged News
Novita's Fascin Inhibitor NP-G2-044 Shows Promising Results in Phase 2 Trial for Advanced Solid Tumors
• Novita Pharmaceuticals' first-in-class fascin inhibitor NP-G2-044 demonstrated a 21% objective response rate and 76% disease control rate in patients with advanced solid tumors resistant to prior anti-PD-1 therapy.
• The Phase 2 trial showed durable responses across seven cancer types, with 55% of patients experiencing no new metastases and some responses lasting more than 80 weeks in pancreatic and endometrial cancers.
• NP-G2-044 targets fascin, a key protein in tumor cell motility, potentially addressing the critical unmet need for therapies specifically targeting cancer metastasis, which causes over 90% of cancer-related deaths.
Related Clinical Trials:
Novita Pharmaceuticals, Inc.
Posted 12/7/2021
Bayer Partners with ConcertAI to Accelerate Precision Oncology Drug Development Using AI
• Bayer and ConcertAI have entered a multi-year strategic agreement leveraging AI and machine learning to accelerate clinical development in precision oncology.
• The partnership utilizes ConcertAI's Translational360™ platform, which integrates data from over 9 million cancer patient records across the U.S., combining clinical, genomic, and imaging information.
• This collaboration aims to enhance drug discovery by using multi-modal data and AI to better predict treatment responses, potentially delivering precision oncology treatments to patients faster.
1Cell.Ai Launches OncoIncytes: Revolutionary Multi-Modal Cancer Diagnostic Panel for Precision Oncology
• 1Cell.Ai (formerly OneCell Diagnostics) has launched OncoIncytes, a comprehensive multi-modal cancer diagnostic panel that integrates ctDNA, CTCs, RNA transcriptomics, and proteomics data for enhanced precision oncology.
• The technology employs a 1080 gene panel with AI and machine learning models, offering unprecedented sensitivity to optimize clinical trials, particularly for antibody-drug conjugate development.
• Following a $16M Series A funding round, the company's rebranding reflects its evolution from genomics-based diagnostics to AI-powered precision oncology solutions aimed at revolutionizing cancer care.
Guardant Health's Shield Multi-Cancer Detection Test Shows Strong Performance Across 10 Cancer Types
• Guardant Health's blood-based Shield Multi-Cancer Detection test demonstrated 98.5% specificity and 60% overall sensitivity across ten tumor types, with particularly strong results for aggressive cancers.
• The test achieved 89% accuracy for cancer signal of origin prediction, potentially enabling clinicians to identify the primary tumor location through a simple blood draw.
• Based on these promising results, the National Cancer Institute selected Shield MCD for its upcoming Vanguard Study evaluating emerging multi-cancer detection technologies.
Personalis to Present New Data on NeXT Personal ctDNA Test for Early Cancer Detection at Major Oncology Conferences
• Personalis and academic collaborators will showcase new clinical data on their ultrasensitive NeXT Personal ctDNA assay at upcoming AACR and ASCO conferences, demonstrating its application across multiple cancer types.
• The VICTORI study will present preliminary results on post-surgical minimal residual disease detection in colorectal cancer, while the TRACERx collaboration will share findings from one of the largest ctDNA studies in early-stage lung cancer.
• New research will expand clinical evidence for NeXT Personal into neoadjuvant treatment settings for breast cancer and cervical cancer, supporting the company's mission to enable earlier detection of residual and recurrent cancer.
Cemiplimab Shows Significant Survival Benefit in NSCLC Patients with Brain Metastases and High PD-L1 Expression
• First-line cemiplimab (Libtayo) monotherapy demonstrated a remarkable survival advantage over chemotherapy in advanced NSCLC patients with PD-L1 ≥50% and brain metastases, with median OS of 52.4 vs 20.7 months.
• The EMPOWER-Lung 1 trial's 5-year follow-up data confirms cemiplimab's long-term clinical benefits across all PD-L1 expression levels, with the greatest benefit observed in patients with PD-L1 ≥90%.
• Patients receiving cemiplimab experienced fewer grade ≥3 adverse events compared to chemotherapy (18.3% vs 39.9%), while also reporting improved quality of life measures including better emotional functioning and reduced fatigue.
Related Clinical Trials:
Regeneron Pharmaceuticals
Posted 5/29/2017
Balancing Efficacy and Cost Sustainability in Modern CLL Treatment: Insights from Dr. Pierluigi Porcu
• Clinicians treating chronic lymphocytic leukemia (CLL) face growing challenges in balancing clinical efficacy with long-term cost sustainability, requiring a holistic approach to patient care.
• Dr. Pierluigi Porcu emphasizes that effective CLL management requires understanding disease risk, patient comorbidities, and practice environment constraints including payer considerations.
• Despite its importance, value-based care adoption remains insufficient in oncology, with challenges in defining and measuring value across patient outcomes, quality of life, and treatment costs.
Related Clinical Trials:
Acerta Pharma BV
Posted 2/25/2019
Stichting European Myeloma Network
Posted 12/14/2018
Porton Advanced Accelerates Development of Innovative Cell Therapies for Solid Tumors with Key Partnerships
• Porton Advanced's CDMO services have enabled Tasly Pharmaceutical's dual-targeting CAR-T therapy for recurrent glioblastoma to receive IND approval from China's NMPA, demonstrating the effectiveness of their end-to-end manufacturing platform.
• The company has established a new partnership with Hualong Biological to accelerate the development of Multi-Activated T Cell (MATC) therapy for solid tumors, leveraging Porton's regulatory expertise and manufacturing capabilities.
• With 18 global IND approvals and specialized platforms for plasmids, viral vectors, and cell therapies, Porton Advanced is positioning itself as a leading CDMO in the advanced therapy medicinal products (ATMPs) sector.
Dual-Modal Approach Combining OCT and Raman Spectroscopy Achieves 97% Accuracy in Skin Cancer Detection
• A novel dual-modal approach combining optical coherence tomography (OCT) and Raman spectroscopy has demonstrated 96.9% accuracy in differentiating melanoma from benign lesions when paired with machine learning algorithms.
• Early melanoma detection significantly impacts patient outcomes, with 5-year survival rates dropping from 99% in early-stage cases to just 35% when the cancer metastasizes to distant organs.
• This non-invasive diagnostic technique could potentially reduce reliance on painful biopsies while providing clinicians with more objective and rapid diagnostic capabilities for skin cancer.
FDA Approves Theratechnologies' EGRIFTA SV Prior Approval Supplement and Alpha Tau's Trial for Recurrent Glioblastoma
• Theratechnologies has received FDA approval for a Prior Approval Supplement (PAS) for EGRIFTA SV, paving the way for its replacement with the new EGRIFTA WR formulation while ensuring continued distribution of EGRIFTA SV.
• Alpha Tau has secured FDA approval to initiate a clinical trial evaluating its Alpha DaRT technology for patients with recurrent glioblastoma, representing a potential new treatment approach for this aggressive brain cancer.
• Both regulatory milestones highlight ongoing innovation in specialized therapeutic areas, with Theratechnologies focusing on metabolic conditions and Alpha Tau advancing novel radiation technology for difficult-to-treat cancers.